4 results about "Bifunctional Antibodies" patented technology

The application relates to a hepcidin chemiluminescence immunoassay kit and a non-diagnostic method for detecting hepcidin, the kit comprising a calibrator, a quality control, an integrated bifunctional antibody reagent, a magnetic particle reagent, a cleaning solution and a chemiluminescence substrate solution; the integrated bifunctional antibody reagent is a buffer containing HEP-specific antibodies covalently connected with fluorescein isothiocyanate and alkaline phosphatase through pH-sensitive connecting bonds; the magnetic particle reagent is a magnetic microsphere suspension coated with a goat anti-fluorescein isothiocyanate antibody; the cleaning solution is a buffer containing a surfactant composition, and the surfactant composition comprises nonionic surfactants, zwitterionic surfactants and high-molecular nonionic surfactants. The hepcidin chemiluminescence immunoassay kit has the effects of ultra-low background noise, ultra-high sensitivity, ultra-wide linear range and simplified operation of end users by means of the integrated bifunctional antibody reagent and the surfactant composition cleaning solution.

The present application provides a bispecific antibody targeting PD-L1 and FasL, which comprises: (a) a PD-L1 antibody capable of specifically binding to PD-L1, and (b) a FasL antibody or a Fas extracellular domain, a truncated or mutant of the Fas extracellular domain, capable of specifically binding to FasL; wherein the heavy chain variable region and the light chain variable region of the FasL antibody are connected to the heavy chain variable region and the light chain variable region of the PD-L1 antibody through a linker sequence, and / or the Fas extracellular domain is connected to the constant region of the PD-L1 antibody through a linker sequence. The present application comprises a preparation method of the molecule and its use as an anticancer drug. The bispecific antibody of the present application comprises a fragment capable of binding to PD-L1 and a fragment specifically binding to FasL, and such bifunctional antibody molecule can produce a synergistic effect and play a high-efficiency antitumor role. Compared with the administration of either of the two antibodies alone, the bispecific antibody of the present application shows a significant synergistic effect in cancer therapy.

The invention relates to the technical field of biology, in particular to a bifunctional antibody for promoting wound healing reaction and a pharmaceutical composition thereof, at least comprising: a first protein functional region targeting CD4, the first protein functional region being an anti-CD4 antibody or an antigen binding fragment thereof; a second protein functional region, the second protein functional region targeting TGF [beta] 1 / [beta] 2 (especially not targeting TGF [beta] 3), the second protein functional region being an anti-TGF [beta] 1 / [beta] 2 (especially not anti-TGF [beta] 3) antibody or an antigen binding fragment thereof; the double antibody can be safely combined with CD4, but the function of the CD4 is not influenced; by combining with CD4, the double antibody can specifically inhibit a TGF-beta1 signal of CD4 + T cells, so that the inhibition effect of TGF-beta1 on the CD4 + T cells is relieved, and the wound healing reaction mediated by the TGF-beta1 is released; meanwhile, the double antibodies can inhibit TGF-beta2 so as to inhibit the fibrosis promotion capability of the TGF-beta2, and have no inhibition capability on TGF-beta3, so that the wound healing promotion capability of the double antibodies is reserved, and the double antibodies can be used for reducing the scar area after wound healing.

The present invention relates to the technical field of biology, particularly to a bifunctional antibody for treating systemic sclerosis and a pharmaceutical composition thereof, the bifunctional antibody at least comprises: a first protein functional region targeting CD4, the first protein functional region being an anti-CD4 antibody or an antigen binding fragment thereof; the second protein functional region is targeted to TGF [beta] 1 / [beta] 2 / [beta] 3, and the second protein functional region is an anti-TGF [beta] 1 / [beta] 2 / [beta] 3 antibody or an antigen binding fragment of the anti-TGF [beta] 1 / [beta] 2 / [beta] 3 antibody; the double antibody can be safely combined with CD4, but the function of the CD4 is not influenced; through combination with CD4, the double antibody can specifically inhibit a TGF-beta1 signal of CD4 + T cells, so that the inhibition effect of TGF-beta1 on the CD4 + T cells is relieved, and a tissue repair reaction mediated by the TGF-beta1 is released; meanwhile, the double antibodies can inhibit TGF-beta2 and TGF-beta3, so that the fibrosis promoting capability of the double antibodies is inhibited, and the double antibodies can be used for treating systemic sclerosis.